Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
Consano Bio
Modality
UNKNOWN
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07264270CT.gov Study to Evaluate Safety of C-1101 Versus Sterile Saline in Adults With Chronic Painful Lumbosacral Radiculopathy | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Indicative
Detailed axis rationale is planned and will be published soon.
Same indication · Radiculopathy
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| c-1101 (this asset) | Consano Bio | P1 | CC · 43 |
| Kenacort | University of Miami | P4 | BBB |
| Lidocaine | Sheba Medical Center | P4 | BBB |
| sp-102 | Semnur Pharmaceuticals, Inc. | P3 | BB |
| Dexasone | Semnur Pharmaceuticals, Inc. | P4 | BB |
| Celestone | Sheba Medical Center | P4 | BB |
| Marcaine | Express Specialty Pharmacy | P3 | BB |
| Artemin | Biogen | P2 | BB |
| Pregabalin | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | P3 | B |
+27 more in the Radiculopathy cohort
Other indications for c-1101
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Sciatica | — | P1 | NR |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. c-1101 in Radiculopathy. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/c-1101-radiculopathy
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →